Author:
Sahasrabudhe Siddhee A.,Bonate Peter L.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Center For Drug Evaluation and Research Application Number: 209819Orig1s000 Clinical Pharmacology and Biopharmaceutics Review(S) [Sublocade®]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000ClinPharmR.pdf Accessed 23 July 2022
2. Lanke S, Shoaf SE (2019) Population pharmacokinetic analyses and model validation of tolvaptan in subjects with autosomal dominant polycystic kidney disease. J Clin Pharmacol 59(5):763–770. https://doi.org/10.1002/jcph.1370
3. Ralph LD, Sandstrom M, Twelves C, Dobbs NA, Thomson AH (2006) Assessment of the validity of a population pharmacokinetic model for epirubicin. Br J Clin Pharmacol 62(1):47–55. https://doi.org/10.1111/j.1365-2125.2006.02584.x
4. Comets E, Ikeda K, Hoff P, Fumoleau P, Wanders J, Tanigawara Y (2003) Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 30(4):257–283. https://doi.org/10.1023/A:1026142601822
5. Reporting and Analysis Plan (RAP) for Dose Escalation and Target Engagement Interims (GSK2330811). https://clinicaltrials.gov/ProvidedDocs/25/NCT03041025/SAP_001.pdf Accessed 23 July 2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献